Until recently, most manufacturers have focused on the development of abuse-deterrent opioid formulations for extended-release/long-acting (ERLA) opioid analgesics. In general the amount of opioid in an ERLA product is greater than the amount found in IR formulations, and the extraction of the opioid or the defeat of the extended-release mechanism for the ERLA opioids results in greater amounts of drug available for abuse by various routes of administration. However, IR opioids are abused as well, and the development of abuse-deterrent formulations for these products is also an important public health goal.
While the FDA is not bound to the recommendations, the agency typically follows the advice of the advisory committees. If approved, Avridi will be indicated for the management of pain severe enough to require an opioid analgesic and for which alternative options are inadequate.
For more information call (888) 463-6332 or visit FDA.gov.